The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rate of durable complete remission (CR) using two sequential, dose-dense regimens of cisplatin, gemcitabine, paclitaxel (CGP) followed by m-VAC in patients with metastatic urothelial cancer (mUC).
Matteo Brighenti
No relevant relationships to disclose
Stefano Panni
No relevant relationships to disclose
Bruno Perrucci
No relevant relationships to disclose
Mariangela Maltese
No relevant relationships to disclose
Wanda Liguigli
No relevant relationships to disclose
Gianluca Tomasello
No relevant relationships to disclose
Rossana Poli
No relevant relationships to disclose
Federica Negri
No relevant relationships to disclose
Margherita Ratti
No relevant relationships to disclose
Maddalena Donini
No relevant relationships to disclose
Laura Toppo
No relevant relationships to disclose
Carlo del Boca
No relevant relationships to disclose
Luigi Benecchi
No relevant relationships to disclose
Andrea Prati
No relevant relationships to disclose
Daniel Martens
No relevant relationships to disclose
Michele Potenzoni
No relevant relationships to disclose
Rodolfo Passalacqua
No relevant relationships to disclose